Milestone Pharmaceuticals Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Milestone Pharmaceuticals Inc Unternehmen

Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.

Milestone Pharmaceuticals Inc Informationen



BörsenkürzelMIST

Name des UnternehmensMilestone Pharmaceuticals Inc

IPO-datumMay 09, 2019

CEOOliveto (Joseph)

Anzahl der mitarbeiter33

WertpapierartOrdinary Share

GeschäftsjahresendeMay 09

Addresse420-1111 boul. Dr.-Frederik-Philips

StadtMONTREAL

BörseNASDAQ OMX - NASDAQ BASIC

LandCanada

PostleitzahlH4M 2X6

Telefon15143360444

Websitehttps://www.milestonepharma.com

BörsenkürzelMIST

IPO-datumMay 09, 2019

CEOOliveto (Joseph)

Führungskräfte von Milestone Pharmaceuticals Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Bharucha

Chief Medical Officer

128.30K

+7855.00%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

119.05K

+7855.00%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+50000.00%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Joseph Oliveto

President, Chief Executive Officer, Director

--

Ms. Lisa M. Giles

Independent Director

--

Mr. Lorenz Muller

Chief Commercial Officer

--

Mr. Seth H. Z. Fischer

Independent Director

--

Mr. Jeffrey Nelson

Chief Operating Officer

--

Mr. Stuart Duty

Independent Director

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. David Bharucha

Chief Medical Officer

128.30K

+7855.00%

Mr. Amit Hasija

Chief Financial Officer, Executive Vice President - Corporate Development

119.05K

+7855.00%

Dr. Robert James Wills, Ph.D.

Non-Executive Independent Chairman of the Board

65.00K

+50000.00%

Mr. Michael John Tomsicek

Independent Director

15.00K

--

Mr. Joseph Oliveto

President, Chief Executive Officer, Director

--

Ms. Lisa M. Giles

Independent Director

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Mon, Nov 17

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Simplify Asset Management Inc

9.34%

Adage Capital Management, L.P.

8.19%

Propel Bio Management, LLC

6.02%

Trails Edge Capital Partners LP

4.50%

OrbiMed Advisors, LLC

3.78%

Andere

68.16%

Aktionäre

Anteil

Simplify Asset Management Inc

9.34%

Adage Capital Management, L.P.

8.19%

Propel Bio Management, LLC

6.02%

Trails Edge Capital Partners LP

4.50%

OrbiMed Advisors, LLC

3.78%

Andere

68.16%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

16.52%

Hedge Fund

14.43%

Venture Capital

6.24%

Research Firm

5.04%

Individual Investor

3.97%

Investment Advisor/Hedge Fund

3.95%

Private Equity

3.78%

Family Office

1.17%

Bank and Trust

0.02%

Andere

44.87%

Institutionelle Beteiligung



Aktualisiert: Thu, Jan 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

118

42.48M

49.88%

+14.49M

2025Q3

99

19.38M

22.80%

-5.64M

2025Q2

99

14.54M

18.86%

-15.65M

2025Q1

102

12.26M

22.94%

-17.24M

2024Q4

99

25.17M

47.19%

-9.38M

2024Q3

113

29.31M

55.02%

-13.44M

2024Q2

115

30.81M

57.87%

-11.80M

2024Q1

116

31.96M

60.43%

+3.19M

2023Q4

112

18.49M

55.02%

-13.59M

2023Q3

109

20.24M

60.32%

-12.06M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Simplify Asset Management Inc

7.96M

9.34%

+5.18M

+186.09%

Sep 30, 2025

Adage Capital Management, L.P.

6.98M

8.19%

+6.98M

--

Sep 30, 2025

Propel Bio Management, LLC

5.12M

6.02%

+4.27M

+502.93%

Jul 11, 2025

Trails Edge Capital Partners LP

3.83M

4.5%

-1.50M

-28.13%

Sep 30, 2025

OrbiMed Advisors, LLC

3.22M

3.78%

+3.22M

--

Sep 30, 2025

Oliveto (Joseph Gerard)

2.51M

2.95%

+66.67K

+2.73%

Jul 11, 2025

Morgan Stanley & Co. LLC

2.63M

3.09%

+1.81M

+221.87%

Sep 30, 2025

RTW Investments L.P.

2.51M

2.94%

--

Sep 30, 2025

Pathstone

1.00M

1.17%

+1.00M

--

Sep 30, 2025

Two Sigma Investments, LP

900.59K

1.06%

+900.59K

--

Sep 30, 2025

Verbundene ETFs



Aktualisiert: Tue, Dec 2

Name

Anteil

Simplify Propel Opportunities ETF

8.04%

SPDR S&P International Small Cap ETF

0.01%

Avantis US Small Cap Equity ETF

0%

Simplify Propel Opportunities ETF

Anteil8.04%

SPDR S&P International Small Cap ETF

Anteil0.01%

Avantis US Small Cap Equity ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten

Datum

Ex-Dividendentag

Art

Verhältnis

Keine Daten